What Is Cortexin?

1. Is Cortexin a peptide or a brain extract?

Cortexin contains many peptides. GEROPHARM’s English product information describes polypeptides from cattle cerebral cortex, supplied as a freeze-dried preparation. “Cortexin peptide” is convenient shorthand, but there is no single amino-acid sequence or molecular weight for the entire product.

The official product site lists 10 mg of Cortexin and 12 mg of glycine per adult vial. The glycine stabilizes the preparation. Total powder mass therefore differs from the labeled amount of Cortexin, and neither number reveals the amount of each individual peptide.

This makes product identity more complicated than it is for Semax, a defined seven-amino-acid peptide. A generic vial labeled “cortex peptides” cannot be assumed equivalent to the preparation used in a trial. A purity percentage needs a defined substance and analytical method behind it.

2. How might Cortexin affect the brain?

Researchers study Cortexin mainly as a neuroprotective agent: a substance that might reduce damage to neurons under stress.

In Yakovlev and colleagues’ 2017 experiments, Cortexin inhibited caspase-8, an enzyme involved in initiating cell-death signaling. Both the original mixture and an isolated peptide fraction reduced neuronal damage in a culture exposed to glutamate. Excessive glutamate signaling can injure neurons. Protecting cells in that experiment does not demonstrate stronger memory in people.

Kurkin and colleagues’ 2021 study reported less brain injury and better neurological performance in rats with experimentally reduced brain blood flow. Separate laboratory assays found interactions with glutamate and GABA receptors, which participate in excitatory and inhibitory signaling.

The same paper measured radioactive tracer in mouse brain tissue at roughly 6–8% of the level in whole blood after 30 minutes. That is a brain-to-blood measurement, not proof that 6–8% of an injected dose reaches a human brain intact. It also cannot identify which components caused a benefit. Pharm-Holding funded the study, and three authors were company employees.

Claims about BDNF, neuroplasticity or “growing new neurons” need their own measurements. None of the findings above establishes a percentage increase in human learning speed.

3. What do human Cortexin studies show?

The clinical literature concerns people with illness or neurological impairment. Sample size helps assess precision, but a large uncontrolled study still cannot isolate a drug effect.

The 272-person stroke trial needs a second source

The original 2014 report describes favorable recovery after ischemic stroke, when a blocked blood vessel interrupts brain blood supply. Its abstract provides no usable numerical between-group estimate of functional benefit.

The 2023 Cochrane review examined that trial and could not extract usable functional outcomes from the published graphs. Reviewers found no registered protocol and judged several bias domains unclear.

They recorded seven deaths among 208 participants assigned to Cortexin-containing regimens and none among 64 assigned to placebo alone. Investigators judged the deaths unrelated to treatment. These sparse data cannot establish that Cortexin caused the deaths or reliably exclude harm.

The review’s seven trials totaled 1,773 people, but only 272 received assignment in the Cortexin trial. The rest studied Cerebrolysin. Its finding of increased nonfatal serious adverse events with Cerebrolysin must not be presented as a Cortexin-specific risk estimate.

What the newer 490-person study adds

In the 2025 route-comparison trial, 93.64% of the IV-first group and 86.50% of the IM group reached a modified Rankin score of 0–2 at day 90, indicating no more than slight disability. Both groups later received IM Cortexin.

The abstract calls the trial placebo-controlled because participants also received dummy injections through the other route. Everyone received active drug. Natural recovery and rehabilitation therefore remain part of the improvement in both groups. The study did not test healthy-user memory, and its reported cognitive-score changes did not differ significantly between routes (p = 0.249).

4. Does Cortexin improve memory and focus in healthy adults?

The reviewed studies do not provide a reliable estimate. A person regaining function after a stroke starts from a different baseline than someone trying to remember more of a book or work with fewer distractions.

Two citations can make the evidence look stronger than it is. “Influence of Cortexin on memory and attention,” by Tsyganov and Bogoslovskii, is a 2004 review. Its title does not identify a placebo-controlled experiment in healthy volunteers.

The Mashin paper refers to a program involving 50,000 patients across 70 Russian cities. The published analysis covered 500 people with stage II brain ischemia, with a mean age of about 64. It was an open treatment study. Calling it a “50,000-person clinical trial proving memory enhancement” would misstate both the sample and the design.

A useful healthy-user trial would measure retained learning, attention errors or working memory against placebo, then check whether benefits persist. Feeling more alert and remembering more a week later are separate outcomes.

5. Cortexin for brain fog, fatigue and long COVID

The 2022 CORTEX program followed 979 people with post-COVID symptoms, including fatigue and impaired concentration. Researchers assessed patients at consultation, around days 10–14, and day 30, and reported improvement after treatment.

Without a placebo or untreated comparison, the program cannot determine how much change came from Cortexin. Symptoms can fluctuate, participants can improve with time, and repeated cognitive testing can improve scores. The report supports further investigation; it does not establish a treatment for every cause of brain fog.

The 2026 DIACORT study adds randomized evidence in a different population: people with type 2 diabetes and neurological complications. Both groups received background treatment; one also received Cortexin. The abstract reports a 1.2-fold increase in average MoCA cognitive-screening score in the Cortexin group after three months, alongside other favorable outcomes.

A 1.2-fold screening-score change is not a 20% increase in intelligence. The abstract lacks enough detail about blinding and absolute between-group cognitive changes to support that interpretation. Neither study tested healthy adults.

6. Cortexin vs Cerebrolysin, Semax and Pinealon

The 2021 rat experiment compared Cortexin and Cerebrolysin, but it cannot establish which improves human cognition more. Comparing their milligram amounts also cannot produce a potency ratio: each milligram represents a different mixture.

The EDR review by Khavinson and colleagues traces Pinealon’s sequence to Cortexin. An isolated sequence does not inherit every effect reported for its source mixture, and the mixture does not inherit every finding about the isolated peptide.

No controlled healthy-user trial of Cortexin combined with Cerebrolysin, Semax or Selank was identified in the sources reviewed here. Combining them also makes an experience report harder to interpret: a change in sleep, mood or concentration could come from several exposures.

7. Cortexin dosage, injections and oral products

There is no validated Cortexin dose or cycle for cognitive enhancement. The 2018 patient study tested 10 mg and 20 mg daily over 10-day courses in chronic cerebral ischemia. Those are study regimens for diagnosed disease, not established regimens for improving memory and focus in healthy adults.

The route information deserves care. The manufacturer’s website now describes IM and IV formulations, while its linked 10 mg patient leaflet explicitly instructs intramuscular use and prohibits intravenous or subcutaneous administration. The documents are inconsistent. An IV study cannot authorize changing the route of an IM-labeled vial.

The reviewed clinical studies also do not establish equivalent benefits from oral capsules, nasal sprays or subcutaneous products. Each formulation needs evidence about absorption, exposure and outcomes. A familiar compound name cannot supply those measurements.

8. Cortexin half-life and how long effects last

A dependable human half-life for the whole mixture was not established in the reviewed sources. Different components may distribute and break down differently. Claims that effects persist for weeks or months describe a proposed duration of benefit, rather than a measured clearance rate.

Likewise, the mouse tracer experiment measured radioactivity at a particular time. It did not establish how quickly half of the active preparation disappears from human blood or brain.

Entering a guessed value into a peptide half-life model will generate a curve. It cannot reveal Cortexin accumulation or validate the next administration time. A useful pharmacokinetic study would need to specify which components it measured and how those measurements relate to biological effects.

9. Cortexin side effects and safety

The manufacturer’s patient leaflet lists allergic reactions, headache, dizziness, drowsiness, agitation, anxiety, insomnia, fast or irregular heartbeat, and increased blood pressure. It categorizes these as very rare. Those labeling categories do not quantify risk from an online product or repeated nootropic cycles.

The leaflet also lists anaphylaxis and airway swelling. Breathing difficulty, facial or throat swelling, or collapse after exposure require emergency medical care.

In the 272-person stroke trial assessed by Cochrane, adverse events occurred in 31 of 208 participants across the Cortexin groups and 7 of 64 on placebo. The estimate was imprecise: risk ratio 1.38, 95% confidence interval 0.63–3.03. This does not demonstrate equal safety, and stroke-patient events do not predict a healthy user’s risk.

Product quality adds a separate uncertainty. Identity, composition, sterility and endotoxin contamination require different assessments. A certificate reporting peptide purity cannot establish all four, or tell you whether repeated exposure is safe.

10. How can you judge a claim about Cortexin?

Start with the outcome you care about. Remembering names, sustaining attention, recovering from illness and feeling energetic require different measurements. A study should identify the exact preparation, compare it with an appropriate control, and report both performance and unwanted effects.

For personal records, note sleep, caffeine, medications, illness and baseline performance alongside any perceived change. Repeating the same memory test can produce practice gains. Starting a log during an unusually bad week can make a return to normal look like a treatment effect.

Persistent or worsening cognitive symptoms deserve clinical assessment. A dated record of when they began, how they affect daily tasks and what else changed gives a clinician more useful information than a general rating of “brain fog.”

11. Cortexin FAQ

• What is Cortexin made from?

  Cortexin contains a mixture of peptides extracted from animal cerebral cortex. GEROPHARM's English product information identifies cattle cortex. The branded 10 mg vial also contains 12 mg of glycine as a stabilizer.

• Does Cortexin improve memory or focus?

  Patient studies report some favorable findings, but the research reviewed here does not establish reliable cognitive enhancement in healthy adults. Recovery from neurological illness and improvement above a healthy baseline are different outcomes.

• Can Cortexin help with brain fog or long COVID?

  A 979-person observational post-COVID program reported improvement in cognitive and fatigue symptoms. It lacked a placebo or untreated comparison, so it cannot separate a drug effect from recovery, expectation or other care.

• Is Cortexin better than Cerebrolysin?

  No reliable human head-to-head evidence for healthy-user cognition was identified. The products are different animal-derived mixtures. A rat comparison cannot establish a human potency ratio or prove that one improves memory more.

• Is there a recommended Cortexin dosage for memory and focus?

  There is no validated cognitive-enhancement dose or cycle for healthy people. Medical regimens studied in patients do not establish a safe self-experimentation schedule.

• Can Cortexin be taken orally or subcutaneously?

  The reviewed trials do not validate oral or subcutaneous Cortexin for cognitive enhancement. An intravenous formulation has been studied, but the linked patient leaflet explicitly restricts its product to intramuscular use. Formulations and their instructions must not be treated as interchangeable.

• What is Cortexin's half-life?

  The reviewed sources do not establish one dependable human half-life for the whole mixture. Animal tracer measurements and claims of lasting benefits cannot supply a human clearance rate.

• What are Cortexin's side effects?

  The manufacturer's patient leaflet lists allergic reactions, headache, dizziness, drowsiness, agitation, anxiety, insomnia, fast or irregular heartbeat, and increased blood pressure. Severe allergic reactions require emergency care. These reports do not quantify the safety of repeated use to improve memory and focus.

12. Sources